{"filing":{"accession_number":"0001714899-26-000070","cik":"0001714899","ticker":"DNLI","company_name":"Denali Therapeutics Inc.","form":"8-K","filing_date":"2026-05-22","report_date":null,"primary_document":"dnli-20260521.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489926000070/dnli-20260521.htm"},"events":[{"id":10732,"run_id":9414,"accession_number":"0001714899-26-000070","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The disclosure announces topline results from a Phase 2b clinical trial (LUMA study) for BIIB122 (DNL151), a Parkinson's disease candidate co-developed with Biogen. While clinical trial results are material to investors evaluating the company's pipeline and prospects, this does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, or other enumerated event types). The Regulation FD disclosure format and emphasis on trial outcomes support classification as a material event outside the specific categories.","company_name":"Denali Therapeutics Inc.","ticker":"DNLI","filing_date":"2026-05-22","form":"8-K","submitted_at":null,"items":[{"id":7117,"accession_number":"0001714899-26-000070","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces topline results from a Phase 2b clinical trial (LUMA study) for BIIB122 (DNL151), a Parkinson's disease candidate co-developed with Biogen. While clinical trial results are material to investors evaluating the company's pipeline and prospects, this does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, or other enumerated event types). The Regulation FD disclosure format and emphasis on trial outcomes support classification as a material event outside the specific categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:58:59.772328+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7117,"accession_number":"0001714899-26-000070","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces topline results from a Phase 2b clinical trial (LUMA study) for BIIB122 (DNL151), a Parkinson's disease candidate co-developed with Biogen. While clinical trial results are material to investors evaluating the company's pipeline and prospects, this does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, or other enumerated event types). The Regulation FD disclosure format and emphasis on trial outcomes support classification as a material event outside the specific categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:58:59.772328+00:00","company_name":"Denali Therapeutics Inc.","ticker":"DNLI","filing_date":"2026-05-22"}]}